MedTrace Logo

Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)

NCT00726609 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 214

Last updated 2015-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this postmarketing surveillance study is to collect an extensive body of data in a large patient population in every day life to investigate the safety and efficacy of NOXAFIL® (posaconazole) in the treatment of invasive fungal disease.

Conditions

  • Mycoses

Interventions

DRUG

Posaconazole

The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-07-31
Completion
2008-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726609 on ClinicalTrials.gov